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Abstract objective The number of adults with diabetes in sub-Saharan Africa (SSA) is expected to almost
double by 2035. This study investigated the prevalence of diabetic retinopathy (DR) and its risk
factors at entry into a community-based screening programme.
methods All persons with diabetes screened for retinopathy at entry into a screening programme in
Kilimanjaro Region, Tanzania between November 2010 and December 2014 were included. Fundus
photographs were taken with a Topcon retinal camera following pupil dilation. Data were collected
on BP, random blood sugar, duration of diabetes, BMI and visual acuity on entry.
results A total of 3187 persons were screened for DR. The prevalence of any DR was 27.9%
(95%CI 26.4–29.5%) with background diabetic retinopathy (BDR), pre-proliferative diabetic
retinopathy (PPDR) and proliferative diabetic retinopathy (PDR) having a prevalence of 19.1% (95%
CI 17.7–20.4%), 6.0% (95%CI 5.2–6.8%) and 2.9% (95%CI 2.3–3.5%), respectively. Maculopathy
was present in 16.1% (95%CI 14.8–17.4%) of participants. Multivariable logistic regression analysis
for the presence of any DR found independent associations with duration of diabetes (P < 0.0001),
systolic BP (P < 0.0001), random blood sugar (P < 0.0001) and attending a government hospital
diabetic clinic (P = 0.0339).
conclusions This study is the first to present data from a DR screening programme in SSA. The
results will provide policymakers with data to aid planning of DR screening and treatment services in
the African region. The study highlights the importance of managing comorbidities within DR
screening programmes.
keywords diabetic retinopathy, screening, Africa
Introduction
Sub-Saharan Africa (SSA) faces a rising epidemic of non-
communicable disease including heart disease, stroke,
cancer and diabetes mellitus [1–4]. It is predicted that by
2030 non-communicable diseases will cause 46% of all
deaths in SSA driven by the changing demographic profile
of the population and as a presumed consequence of
increased urbanisation, with its associated lifestyle
changes including diet, physical inactivity, smoking, alco-
hol use and obesity [5–8].
The number of adults with diabetes mellitus (DM) in
SSA is expected to almost double, from 21.5 million to
41.5 million, by 2035 [9]. Diabetic retinopathy (DR) is
the commonest microvascular complication of DM and
can lead to irreversible blindness [10]. Vision loss can be
prevented through tight glycaemic and BP control thus
reducing microvasular damage and through the early
detection and timely treatment of DR with laser photoco-
agulation and intravitreal agents [11]. As DM and DR
become more prevalent throughout the African region, it
is important that strategies are developed to enable the
early detection and adequate management of this emerg-
ing epidemic.
There are limited data available on the prevalence, inci-
dence and progression of DR in SSA [12]. There is strong
evidence from Europe and the USA on the effect of gly-
caemic control and copathology such as hypertension on
the development on DR. In contrast, there are few data
from African populations that address these questions.
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To effectively plan and develop services to detect and
treat DR in SSA, it is essential that the prevalence of DR
and its associated risk factors within the African region
be investigated.
The Kilimanjaro Diabetic Programme (KDP) was one
of the first regional DR screening and treatment services
to be established in SSA. We report estimates of the
prevalence of DR and its associated risk factors among
individuals with DM, at the time of their entry into this
programme. As this is the first study to report data from
a regional DR screening programme, the results are of
relevance to those developing DR screening and treat-
ment services elsewhere in SSA.
Methods
The total population of Kilimanjaro Region of Northern
Tanzania was reported as 1.64 million in the 2012 census
[13]. The population is distributed across an area of 13
250 km2. 24.2% of the population live in urban areas
with an average household size of 4.3 persons. An esti-
mated 9.7% of the population of Kilimanjaro Region is
older than 60 years, the highest in Tanzania [13].
There are 18 health facilities, including government,
church-based and private hospitals within Kilimanjaro
Region providing services for people with diabetes
(Figure 1). The Kilimanjaro Diabetic Programme (KDP)
is an integrated clinic-based mobile retinal screening ser-
vice that has operated in Kilimanjaro Region since
November 2010. All known persons with diabetes are
registered with the KDP, after providing consent, follow-
ing an appointment at one of the 18 diabetic clinics.
Following registration with the KDP, the patient’s
name, age, diabetic clinic, education level and residence
are entered into a central database at Kilimanjaro Chris-
tian Medical Centre (KCMC) and they are assigned a
unique KDP number. Patients were categorised as living
in an urban or rural area based on residence information.
There are seven districts in Kilimanjaro region and only
patients residing in Moshi Urban District were classified
as living in an urban area. Moshi is the largest town in
Kilimanjaro region with a population of 184 292 [13].
KCMC Eye Department is a tertiary referral centre for
ophthalmology and provides a full range of services
including laser photocoagulation and vitreoretinal sur-
gery. Following registration with the KDP, patients are
then informed when screening will take place and all per-
sons registered with the KDP are invited to attend. The
18 diabetic clinics are each visited approximately one day
per month on dedicated diabetic clinic days.
During DR screening visits, trained retinal photogra-
phers took fundus photographs of all patients using a
Topcon retinal camera (TRC NW8S: Topcon Corpora-
tion, Tokyo, Japan). Two 45° images (disc-centred and
macula-centred views) were taken in each eye; this could
be with or without pupil dilation with topical g-tropica-
mide 1% eye drops, depending on the quality of the
view. Staff from the University of Birmingham (UK),
through the Vision 2020 Links Programme, and an expe-
rienced ophthalmologist trained the retinal photogra-
phers. The images were stored on a laptop and later
uploaded onto a backup hard-drive. Ophthalmology resi-
dents (specialist eye doctors in training) at KCMC graded
all fundus images during the retina component of their
four-year ophthalmology specialist training. All ophthal-
mology residents performing the grading were in either
the third or fourth year of their ophthalmology specialist
training. Two consultant vitroretinal surgeons (WM and
AH) trained all ophthalmology residents on DR grading.
Both received training on DR grading at the University of
Birmingham (UK), through the Vision 2020 Links Pro-
gramme. They randomly selected 10% of the images,
which were regraded for quality control, and individual
feedback was provided to graders on their performance.
The minimum data set outlined in the English and Wales
National Grading scheme was used for DR grading
(Appendix Table A1) [14].
Images are classified in two ways: (i) degree of general
retinopathy (no diabetic retinopathy, background diabetic
retinopathy, pre-proliferative retinopathy or proliferative
retinopathy) and (ii) the degree of maculopathy (no mac-
ulopathy, non-referable maculopathy or referable macu-
lopathy) [14]. Background DR is defined as any
microaneurysms, retinal haemorrhages or exudates; pre-
proliferative retinopathy as any venous beading, venous
loop, blot haemorrhages or intraretinal microvascular
abnormalities; and proliferative retinopathy as any evi-
dence of new vessel growth. Non-referable maculopathy
is defined as any microaneurysm or haemorrhage within
1 disc diameter of the centre of the fovea and referable
maculopathy as any exudates within 1 disc diameter of
the centre of the fovea (Appendix Table A1).
For this study, any DR was defined as the presence of
any of the following: background DR, pre-proliferative
DR, proliferative DR, non-referable maculopathy, referable
maculopathy, previous panretinal photocoagulation, previ-
ous focal laser or any combination of the fore mentioned.
Patients found to have retinopathy requiring further
investigations or treatment are referred to the KCMC
Hospital Eye Department. They are phoned or sent a text
message two weeks after their screening event by a
member of the KDP team and informed that they need
further investigations and possibly treatment and are
advised when they should attend KCMC. Patients are
418 © 2015 The Authors Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
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advised to attend KCMC urgently or within 6 months.
The thresholds for urgent referral are as follows: prolifer-
ative retinopathy, referable maculoapthy, an ungradable
image or other pathology, for example a glaucomatous
disc. Patients with pre-proliferative retinopathy are
advised to attend KCMC Eye Department within
6 months. Patients not requiring further investigation are
informed of this via text message and advised to attend
another screening event after 1 year.
Data on demographics, blood pressure, random blood
sugar, duration of DM, height, weight, visual acuity and
education level are collected during screening events.
These data are recorded on a paper form and later
entered into the central database at KCMC. All data in
this paper were from the KDP database. No KCMC
Hospital data were included.
Statistical analysis
The electronic data were exported from the central KDP
database (MS Access) and analysed using STATA version
13.0. The eye having the worse diabetic retinopathy was
used for the analysis. Characteristics of the study
population were described using means (SD) for continu-
ous variables and absolute numbers with percentages for
categorical variables. Differences in mean values were
compared using the t-test and proportions were compared
with the chi-squared test. Multivariable logistic regression
analysis was used to investigate the relationship between
diabetic retinopathy and a number of explanatory vari-
ables: age, gender, systolic BP, duration of DM, random
blood sugar and clinic type. A backward stepwise selec-
tion procedure was used with a P-value of 0.2 as the cri-
terion for entry of the variables. A P-value of <0.05 was
considered to indicate statistical significance.
Ethical approval
Ethical approval was obtained from the Kilimanjaro
Christian Medical College University ethics committee.
Results
Diabetes mellitus in Kilimanjaro region
As of January 2015, a total of 5729 individuals were reg-
istered with the KDP. Of these, 3072 (53.6%), 1971
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Figure 1 Map of Kilimanjaro Region
and the diabetic clinics. The green dots
indicate government hospitals, the red
dots, church-based hospitals, and the blue
dots, private hospitals. The red and white
striped dot indicates the referral hospital,
Kilimanjaro Christian Medical Centre.
The number next to each dot corresponds
to the total number of persons with
diabetes registered with the Kilimanjaro
Diabetic Programme in each clinic.
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(34.4%) and 686 (12.0%) attended government, church
and private hospitals, respectively. A total of 1221
(21.3%) were from the Moshi urban area, and 3452
(60.3%) were female. Registered females had a median
age of 60 years (IQR 52–69) with a median duration of
DM of 6 years (IQR 4–11). The median age of registered
males was 63 years (IQR 54–72) with a mean duration
of DM of 6 years (IQR 4–12) (Figure 2).
Prevalence of diabetic retinopathy
By December 2014, of the 5729 individuals registered
with the KDP, 3463 (60.4%) had been screened for DR.
Screened patients represent all individuals registered with
the KDP who attended a screening event and had fundus
images taken. The demographic characteristics of individ-
uals who had and had not been screened are shown in
Table 1. Female gender, living in a rural area and attend-
ing a diabetic clinic in either a church or private hospital
were all significantly associated with attendance for reti-
nal screening. However, the Topcon camera was non-
functional for a cumulative total of approximately one
year of the four that the KDP has been running.
Of the 3463 individuals screened, 276 images (8.0%)
were ungradable due to cataract. Therefore, a total of
3187 people had their fundus images graded for DR
(Table 2). The overall prevalence of any diabetic
retinopathy within this group was 27.9% (95% CI
26.4%–29.5%), and the overall prevalence of maculopa-
thy was 16.1% (95% CI 14.8%–17.4%). Proliferative
DR was found in 2.9% (95% CI 2.3%–3.5%). The pro-
portion of individuals with more advanced DR increased
with a longer duration of DM and poorer blood glucose
control, indicated by a random blood sugar of ≥11
(Table 3).
Of the patients screened, 2985 (86.6%), 317 (9.2%)
and 144 (4.2%) were categorised as having mild or no
visual impairment, moderate visual impairment or blind-
ness, respectively, as per WHO classification. Persons
with any diabetic retinopathy were significantly more
likely to have a visual acuity worse than 6 of 18
(Table 4). Education data were available on 2414 of
those screened: 1733 (71.8%) had completed a primary-
level education or less. A total of 2535 (79.5%) of the
patients screened were from rural areas. Patients from
urban areas were significantly younger (P < 0.0001) and
had a higher level of education (P < 0.0001).
Of the 3463 patients screened, 2483 (71.7%) had been
screened once for retinopathy over the four years that the
KDP has been functioning. Of the remaining 980
patients, the number screened for retinopathy two, three,
four and five times were 717 (20.7%), 227 (6.6%), 35
(1.0%) and 1 (0.03%), respectively. After grading of the
baseline fundus images, 1297 (37.5%) patients were
referred to KCMC for further investigation. Of those
referred, 546 (42.1%) presented to KCMC Hospital. The
patients who presented to KCMC following referral were
more likely to be male (OR 1.34, 95% CI = 1.07–1.68)
and were significantly more educated (OR 1.51, 95%
CI = 1.21–1.88). There were no differences in age, cate-
gory of referral hospital (government, church or private)
or residing in an urban or rural area between those who
complied with the follow-up recommendation and those
who did not.
Associations with diabetic retinopathy
The demographic and clinical characteristics of individu-
als with and without any retinopathy are shown in
Table 4. Those with any diabetic retinopathy were signif-
icantly older, had a higher blood pressure, a higher ran-
dom blood sugar, a slightly lower BMI and were
significantly more likely to attend a diabetic clinic in a
government hospital. There were no significant differ-
ences in the presence of any stage of retinopathy or mac-
ulopathy or in DM control (indicated by random blood
sugar) between patients from urban and rural locations.
Multivariable logistic regression analysis revealed that
the duration of diabetes, random blood sugar, systolic
blood pressure and attending a government hospital
diabetic clinic were significantly associated with retinopa-
thy (Table 5).
A number of individuals had missing data for the
parameters entered in the multivariable logistic regres-
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sion model. A large number of BMI measurements were
missing from the data set, and therefore, BMI was
excluded from the multivariable regression model. When
BMI was included, attending a government hospital dia-
betic clinic was no longer significantly associated with
the presence of DR. There were no other changes in
inference.
Discussion
This is the largest study to estimate the prevalence of dia-
betic retinopathy and its associated risk factors in diabetic
patients in sub-Saharan Africa and is the first to report
data from a DR screening service in the region. In this pop-
ulation, the prevalence of any diabetic retinopathy was
Table 1 Characteristics of individuals who have been screened and those who have not been screened for diabetic retinopathy in Kili-
manjaro Region, Tanzania
Characteristic
Not screened Screened
OR (95% CI) P-valuen (%) n (%)
Total 2266 (39.6) 3463 (60.4)
Female* 1264 (36.6) 2188 (63.4) 1.0 (reference)
Male* 1002 (44.0) 1275 (56.0) 0.74 (0.66–0.82) <0.0001
Mean age, years (SD)† 60.9 (15.2) 60.8 (13.0) 1.00 (0.99–1.00) 0.9087
Residence*
Rural 1722 (38.2) 2786 (61.8) 1.0 (reference)
Urban 544 (44.5) 677 (55.5) 0.77 (0.68–0.87) 0.0001
Education‡
No formal education 114 (40.4) 168 (59.6) 1.0 (reference)
Primary-level education 1139 (40.2) 1698 (59.8) 1.01 (0.79–1.30) 0.9278
Secondary-level education 487 (41.6) 685 (58.4) 0.95 (0.73–1.24) 0.7300
College education 12 (48.0) 13 (52.0) 0.74 (0.32–1.67) 0.4619
Clinic type attended*
Government 1461 (47.6) 1611 (52.4) 1.0 (reference)
Missionary 638 (32.4) 1333 (67.6) 1.89 (1.68–2.13) <0.0001
Private 167 (24.3) 519 (75.7) 2.82 (2.33–3.40) <0.0001
*Data available for 5729.
†Data available for 5727.
‡Data available for 4316.
Table 2 Prevalence and grade of diabetic retinopathy and maculopathy, subdivided by gender. Individuals were classified by the eye
with more advanced disease
Clinical stage
Total Male Female
P-valuen (%) (95% CI) n (%) (95% CI) n (%) (95% CI)
Retinopathy
None 2296 72.0 (70.5–73.6) 823 70.4 (67.8–73.0) 1473 73.0 (71.1–75.0)
BDR 607 19.1 (17.7–20.4) 228 19.5 (17.2–21.8) 379 18.8 (17.1–20.5)
PPDR 191 6.0 (5.2–6.8) 81 6.9 (5.5–8.4) 110 5.5 (4.5–6.4)
PDR 93 2.9 (2.3–3.5) 37 3.1 (2.2–4.2) 56 2.8 (2.1–3.5) 0.2639
Total 3187 1169 2018
Maculopathy
None 2648 83.9 (82.6–85.2) 965 83.5 (81.3–85.6) 1683 84.1 (82.5–85.7)
Non-referable 143 4.5 (3.8–5.3) 61 5.3 (4.0–6.6) 82 4.1 (3.2–5.0)
Referable 366 11.6 (10.5–12.7) 130 11.6 (9.4–13.1) 236 11.8 (10.4–13.2) 0.2904
Total 3157 1156 2001
BDR, background diabetic retinopathy; PPDR, pre-proliferative diabetic retinopathy; PDR, proliferative retinopathy. P-values were cal-
culated using by chi-squared to test for differences between males and females in the stages of retinopathy and maculopathy.
© 2015 The Authors Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 421
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27.9%, any maculopathy was 16.1%, proliferative
retinopathy was 2.9%, pre-proliferative retinopathy was
6.0%, and background diabetic retinopathy was 19.1%.
A recent systematic review of DR and maculopathy in
Africa identified 62 studies of DR prevalence with only
nine studies using retinal photographs to grade retinopa-
thy (six of which were conducted in South Africa) [12].
Three population-based studies were identified in the
African region, which estimated the prevalence range of
DR as 30.2–31.6%, proliferative DR as 0.9–1.3% and
any maculopathy as 1.2–4.5% [12]. However, two of
these studies were undertaken in Mauritius and Egypt
(not in SSA) and the third is a population-based study of
visual impairment in adults >40 years old from Nigeria
that did not grade DR or assess maculopathy. We identi-
fied one further population-based survey from Kenya that
was not included in the systematic review, which esti-
mated the prevalence of any DR among persons with dia-
betes as 35.9%, macular oedema as 33.3% and vision-
threatening retinopathy (including clinically significant
macular oedema, severe non-proliferative DR and PDR)
as 13.4% [15]. The remaining studies in the systematic
review were clinic-based and largely from urban popula-
tions. The clinic-based DR prevalence estimates were var-
ied, with any DR ranging from 7.0 to 62.4%,
proliferative DR from 0% to 6.9%, and any maculopa-
thy from 1.2% to 31.1% [12].
The prevalence estimate of any maculoapthy from our
data set is higher than the three population-based esti-
mates included in the systematic review but lower than
the estimate from the survey in Kenya, at 16.1%. This
could be explained by the fact that the definition of any
maculopathy used in our programme and the definition
used in the Kenyan survey included any haemorrhages
within 1 disc diameter of the centre of the fovea, which
could lead to false positives.
WHO estimates the prevalence of diabetes in adults
aged 25–64 years in Tanzania as 9.1% [16]. The number
of persons in Tanzania aged 25–64 years is approxi-
mately 15.3 million [13], of whom an estimated 1.4 mil-
lion have diabetes. If we extrapolate the results of this
study that would suggest there are approximately
390 000 people aged 25–64 years with DR in Tanzania.
Moreover, in this population, the prevalence of prolifera-
tive retinopathy and maculopathy, at 2.9% and 16.1%,
respectively, are both higher than estimates from popula-
tion-based studies in SSA[12] and estimates from Western
populations [17, 18].
In a multivariable analysis, significant associations were
found between the presence of DR and duration of DM,
systolic BP, random blood sugar and attending a govern-
ment diabetic clinic. The effects of copathology on DR
development and progression have been more compre-
hensively studied in Western populations. Studies in the
UK and USA have identified duration of diabetes [19,
20], high HbA1c levels [21, 22] and high blood pressure
[23] as risk factors for DR. Duration of DM is an impor-
tant factor to consider in the implementation of success-
ful DR screening programmes across the region. In low-
income settings, an adjusted follow-up regimen might be
more feasible, with an emphasis on patients with a longer
duration of DM. The recognition and treatment of
suboptimal glycaemic control and hypertension are essen-
tial elements and are important educational messages for
Table 3 Prevalence and grade of diabetic retinopathy and maculopathy in relation to duration of diabetes and random blood glucose.
Individuals were classified by the eye with more advanced disease
Retinopathy Maculopathy
Total BDR n (%) PPDR n (%) PDR n (%) P-value Total NRM n (%) RM n (%) P-value
Duration of DM (years)
0–5 1365 129 (9.5) 43 (3.2) 20 (1.5) 1351 32 (2.4) 64 (4.8)
6–10 913 184 (20.2) 50 (5.5) 22 (2.4) 905 48 (5.3) 102 (11.3)
11–15 466 127 (27.3) 40 (8.6) 26 (5.6) 463 28 (6.1) 88 (19.0)
16–20 206 77 (37.4) 31 (15.1) 9 (4.4) 205 18 (8.8) 60 (29.3)
>20 176 71 (40.3) 26 (14.8) 13 (7.4) <0.0001 173 15 (8.7) 43 (24.9) <0.0001
Total 3126 3097
Random blood sugar
<11 1658 280 (16.9) 97 (5.9) 29 (1.8) 1312 69 (4.2) 152 (9.3)
≥11 1325 292 (22.0) 82 (6.2) 53 (4.0) <0.0001 1644 67 (5.1) 185 (14.1) <0.0001
Total 2983 2956
DM, diabetes mellitus; BDR, background diabetic retinopathy; PPDR, pre-proliferative diabetic retinopathy; PDR, proliferative
retinopathy. NRM, non-referable maculopathy; RM, referable maculopathy. P-values were calculated by chi-squared test to assess the
effect of increasing duration of DM and random blood sugar on the stage of retinopathy and maculopathy.
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both patients and medical staff. Retinal screening activi-
ties need to be well integrated into the general care of
persons with diabetes.
We found a significant correlation between attending a
government hospital diabetic clinic and both lower atten-
dance in the screening programme and an increased risk
of any DR. A possible explanation for this association
could be that patients attending government clinics are
likely to be less affluent and less able to afford clinical
services and medication. In SSA, the less well-off rely
mainly on the public sector for health care, are more
likely to treat themselves and are less likely to use current
preferred treatment options compared to the more well-
off [24]. It is important that screening programmes in
SSA develop strategies to ensure the inclusion of patients
from all socioeconomic levels.
A further concern highlighted in this study was the low
attendance (42.1%) at the central eye unit (KCMC) of
patients who needed further assessment and treatment.
Patients who were male and educated were more likely
to follow the recommendation. As the burden of disease
in SSA shifts to chronic diseases [25], it is essential that
patients are regularly and reliably followed up. Further
studies identifying the patient groups in which follow-up
is low, the reasons for poor follow-up and the evaluation
of strategies to improve follow-up rates are needed.
The strengths of this study include the large number
of people screened, the use of retinal photographs with
a standardised retinopathy grading protocol and the
mobile nature of the KDP covering a large geographi-
cal area, ensuring the inclusion of patients from
both urban and rural populations across Kilimanjaro
Region.
There are currently 5729 people registered with the
KDP, however, only 3187 have been screened and
graded for retinopathy. The main reason for this has
been the necessity to move the retinal camera across the
region on dirt roads, which has caused the camera to
frequently break down. The camera is estimated to have
been non-functional for a cumulative total of one year.
This will have inevitably been a contributory reason for
a number of patients, although registered with the KDP,
not being screened for DR. As these breakdowns
occurred in a random manner and throughout the dura-
tion of the programme, we do not think this would have
introduced any systematic selection or reporting bias.
However, it does highlight the difficulties faced in
accessing, maintaining and fixing expensive equipment
in a low-income setting. Alternative, low-cost equipment
deployed permanently to each remote clinic, which is
easier to maintain and can be used by non-specialists
could increase the number of persons with diabetes
Table 5 Univariate and multivariable logistic regression analysis for factors associated with the presence of any diabetic retinopathy
Variable
Univariate analysis Multivariable logistic regression
OR 95% CI P-value OR 95% CI P-value
Duration of DM (years)
0–5 1.0 – – 1.0 – –
6–10 2.38 1.93–2.94 <0.0001 2.29 1.83–2.86 <0.0001
11–15 4.32 3.40–5.49 <0.0001 3.94 3.05–5.09 <0.0001
16–20 8.03 5.86–11.01 <0.0001 7.57 5.40–10.63 <0.0001
>20 10.18 7.24–14.32 <0.0001 8.05 5.55–11.67 <0.0001
Systolic BP 1.01 1.01–1.02 <0.0001 1.01 1.01–1.01 <0.0001
Random blood sugar 1.04 1.02–1.05 <0.0001 1.04 1.03–1.06 <0.0001
Age 1.02 1.01–1.02 <0.0001 1.01 1.00–1.01 0.0746
Female sex 1.14 0.97–1.33 0.1164 1.06 0.88–1.28 0.5146
Body Mass Index 0.98 0.96–1.00 0.0283 Not included
Clinic type
Non-government 1.0 – – 1.0 – –
Government 1.55 1.33–1.81 <0.0001 1.21 1.02–1.46 0.0339
Education Not included
No formal education 1.0
Primary 0.88 0.61–1.27 0.4944
Secondary 0.85 0.58–1.24 0.3960
College 1.34 0.49–3.68 0.5694
Residence Not included
Rural 1.0
Urban 1.03 0.85–1.24 0.7903
424 © 2015 The Authors Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
Tropical Medicine and International Health volume 21 no 3 pp 417–426 march 2016
C. R. Cleland et al. Diabetic retinopathy screening in Tanzania
who are screened for retinopathy. Although low-cost
alternative devices may increase coverage, it will be
important to compare them to traditional fundus cam-
eras in regards the proportion of ungradable images. In
the KDP, when using a Topcon retinal camera, 8% of
images were ungradable, which compares favourably to
screening programmes in the UK [26].
Although two consultant vitreoretinal surgeons, who
received additional training on grading DR in the UK,
regraded 10% of the images for quality control, there are
no data available on the outcomes of the quality control.
As further DR screening services are established in SSA,
it is important that adequate quality control is incorpo-
rated into screening programmes. This could be through
partnership with accredited international reading centres.
An additional limitation of this study is possible selection
bias. In common with reports from all screening pro-
grammes, it is possible that the underlying prevalence of
DR in persons with diabetes is lower. People who are
known to the health system and who have been screened
by the KDP will probably have had diabetes longer than
those who have not.
The KDP measures random blood sugar during screen-
ing events and does not routinely collect data on HbA1c.
Random blood sugar is a less sensitive marker for blood
glucose control than HbA1c. However, random blood
sugar has been suggested as an alternative to HbA1c in
the African setting [27]. The measurement of random
blood sugar is cheaper, easier and more practical than
HbA1C, especially during mobile screening events. There-
fore, this could be considered as a practical option for
estimating blood glucose control during screening pro-
grammes in a low-income setting.
In conclusion, this is the largest study estimating the
prevalence of DR and its associated risk factors in SSA
and it is the first to publish data from a regional DR
screening programme in SSA. The results emphasize the
high disease burden Tanzania is likely to face from DR
and provides important data for policymakers to aid in
planning DR services in the wider region. Studies identi-
fying the reasons for and strategies to improve follow-up
of patients after screening are necessary to effectively
manage the growing burden of chronic disease in the
African region.
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Appendix
Table A1 The Grading Scheme used in the Kilimanjaro Diabetic Programme based on the minimum data set recom-
mended by the English and Wales National Screening Committee
Retinopathy (R)
Level 0 None
Level 1 Background Microaneurysm(s)
Retinal haemorrhage(s)
Exudate(s)
Level 2 Pre-proliferative Venous beading
Venous loop or reduplication
Multiple deep, round or blot haemorrhages
Intraretinal microvascular abnormality (IRMA)
Level 3 Proliferative New vessels on the disc (NVD)
New vessels elsewhere (NVE)
Pre-retinal or vitreous haemorrhage
Pre-retinal fibrosis
Maculopathy (M)
No Maculopathy Does not meet any of the criteria for maculopathy
Non-referable maculopathy Any microaneurysm or haemorrhage with 1 disc diameter (DD) of the fovea
Referable maculopathy Any exudate within 1 DD of the centre of the fovea
Photocoagulation (P) Focal/grid to macula
Peripheral scatter
Ungradable (U) Ungradable/unclassifiable
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